3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Conditions
Polycystic Ovary Syndrome
9
Hyperandrogenism
4
Neoplasms
3
Skin Diseases
1
Sarcoma
1
Rare Diseases
1
Obesity
1
Metabolic Syndrome
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Hematologic Neoplasms
1
Heart Failure
1
Glioblastoma
1
Endocrine System Diseases
1
Critical Illness
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Breast Neoplasms
1
Advanced Malignant Neoplasm
1
Acute Kidney Injury
1
Acanthosis Nigricans
1
Interventions
sacubitril and valsartan sodium hydrate drug combination
3
Nutrition Assessment
3
Exercise
3
Carvedilol
3
dapagliflozin
2
Standard of Care
2
Rituximab
2
Ivabradine
2
Control Groups
2
Atorvastatin
2
pertuzumab
1
pegfilgrastim
1
obinutuzumab
1
nicotinamide-beta-riboside
1
empagliflozin
1
candesartan
1
acalabrutinib
1
Vincristine
1
Valsartan
1
Trastuzumab
1
Surveys and Questionnaires
1
Spironolactone
1
Sodium Chloride
1
Simendan
1
Secondary Prevention
1
Resistance Training
1
Pyruvic Acid
1
Prednisolone
1
Practice Guidelines as Topic
1
Population Groups
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Heart Failure
×
Spironolactone
×
Clear all
NCT06005259
2023-08-22
SPIROTOX
University of Sao Paulo
Phase 4
Unknown
264 enrolled